Introduction: This may be explained by the presence of the N501Y mutation in the receptor binding domain (RBD) of the spike protein, which enhances viral particle binding to the ACE2 receptor.
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.
Introduction: In particular, B.1.351 variant as a dominant variant in South Africa, characterized by three amino acid mutations on the K417N, E484K, and N501Y in RBD accompanying with four substitutions and a deletion in the N-terminal domain (NTD), decreased neutralization activity of antibodies induced by non-B.1.351 SARS-CoV-2 infection or vaccination and increased transmissibility.
Figure: (A-G) Sera with series of dilution inhibited infection of pseudovirus with or without mutation (WT, B.1.351, P.1, B.1.1.7, D614G, N501Y, E484K).
Figure: (C-F) Inhibition rate of RBD(WT), RBD(
Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants.
PMID: 34228597
2021
Human vaccines & immunotherapeutics
Abstract: Neutralization potency was retained for S variants including S477N, E484K, and N501Y, substitutions present in recent variants of concern.
Introduction: Substitutions N501Y (B.1.1.7) and E484K-N501Y (B.1.351) are present among variants of concern which also posses
Method: E484K-N501Y were escape mutants isolated from 2B04 using N501Y virus.
Method: N501Y and D614G were constructed using SARS-CoV-2 Wuhan-Hu-1 spike with substitution at N501 or D614 site, respectively, and rescued by using reverse genetic system.
Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.
Result: P.1 defining mutations related to each genomic region were the following: ORF1ab: S1188L, K1795Q, E5665D; spike: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I; Orf8: E92K; and nucleocapsid: P80.
Result: The B.1.351 VOC was characterized by K417N, E484K,
Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
Discussion: The set of signature variants includes 8 changes from S protein: deletion 69-70, deletion 144-145, N501Y (A23063T), A570D (C23271A), D614G, P681H (C23604A), T716I (C23709T), S982A (T24506G), D1118H (G24914C).
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.
Discussion: A proportion of RBD-specific mAbs isolated from vaccinated individuals have also demonstrated significant neutralization loss (>50-fold) against N501Y mutants.
Discussion: However, there were differences in particular with S477N, which had the second highest overall affinity (KD) for ACE2 (after N501Y) as determined via BLI but had weaker EC50 compared with Q493L and S494P, respectively.
Discussion: Indeed, the frequency and presence of the N501Y mutation in recently rapidly emerging SARS-CoV-2 lineages, B.1.1.7, B.1.351, B.1.1.70, and P.1, appear to further strengthen this hypothesis, as does the frequency of S477N and S494P, which we find bound ACE2 with
Evolutionary insights into the furin cleavage sites of SARS-CoV-2 variants from humans and animals.
Introduction: The D614G mutation is thought to increase virus transmissibility, while the N501Y mutation has also been implicated in the rapid spread of SARS-CoV-2.
Discussion: Moreover, this mutation is also a characteristic of the newly emerged SARS-CoV-2 variants, which are defined by multiple mutations in the S glycoprotein (Delta69-70, Delta144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H).
SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
Result: Starting with position 501 within a loop in the RDB interacting with the ACE2 receptor, we note that the mutation N501Y does not show any clear structural effect as the negative DeltaDeltaG values are very close to 0.0 kcal/mol in DynaMut.
Table: N501Y
Coding-Complete Genome Sequences of 11 SARS-CoV-2 B.1.1.7 and B.1.351 Variants from Metro Manila, Philippines.
SARS_CoV_2 mutation literature information.
PMID: 
2021
mBio
Browser Board
Co-occurred Entities
Filtrator
ViMRT